Home ›
Breast Cancer Trials ›
NCT07281976
A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer
This trial is an open-label, multicenter phase Ib/II clinical study to evaluate the efficacy and safety of LBL-024 monotherapy or in combination with albumin-bound paclitaxel in patients with recurrent or metastatic triple negative breast cancer(TNBC).
Trial Details
NCT ID NCT07281976
Phase PHASE1 / PHASE2
Sponsor Nanjing Leads Biolabs Co.,Ltd
Status RECRUITING
Cancer Type Breast Cancer
Interventions LBL-024 for Injection albumin-bound Paclitaxel injection Toripalimab Injection
Locations (sample) Guangzhou, Guangdong, China|23.11667,113.25 Guangzhou, Guangdong, China|23.11667,113.25 Harbin, Heilongjiang, China|45.75,126.65 Zhengzhou, Henan, China|34.75778,113.64861 Nanjing, Jiangsu, China|32.06167,118.77778
Key Eligibility Criteria
Agree to follow the trial treatment regimen, visit schedule, laboratory test, and other requirements of the protocol, and voluntarily enroll in the… At the time of signing the informed consent form, the age was ≥ 18 years old. The Eastern Cooperative Oncology Group's physical status scoring standard (ECOG) is 0\~1. The expected survival time is at least 12 weeks.
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Breast Cancer Trials on Trialify →